Design, synthesis and biological evaluation of ligands selective for the melanocortin-3 receptor

Current Topics in Medicinal Chemistry

Volumn 7, Issue 11, 2007, Pages 1085-1097

  Hruby, Victor J ^a   Cai, Minying ^a   Cain, James P ^a   Mayorov, Alexander V ^a   Dedek, Matthew M ^a   Trivedi, Devendra ^a  

^a University of Arizona   (United States)

Author keywords

Agouti related protein; g protein coupled receptors; Mcr signaling; Melanotropin peptide analogues; Proopiomelanocortin

Indexed keywords

ACETYL 4 NORLEUCYLCYCLO[5 ASPARTYL 6 HISTIDYL 7 (2 NAPHTHYLALANYL) 8 ARGINYL 9 TRYPTOPHANYL 10 LYSYL]AMIDE; ACETYLNORLEUCYLCYCLO(ASPARTYLHIDSTIDYL 2 PHENYLALANYLARGINYLTRYPTOPHANYLLYSYL)AMIDE; ACETYLNORLEUCYLCYCLO(ASPARTYLPROLYL DEXTRO 2 NAPHTHYLALANYLARGINYLTRYTOPHANYLLYSL)AMIDE; ALPHA INTERMEDIN; ALPHA INTERMEDIN DERIVATIVE; AVM 75; AVM 76; BETA INTERMEDIN; CORTICOTROPIN; CYCLO[6 (2,3 PYRAZINEDICARBONYL) DEXTRO 7 (2 NAPHTHYLALANYL) 8 ARGINYL 9 TRYPTOPHANYL 10 LYSYL]AMIDE; CYCLO[6 (2,3 PYRAZINEDICARBONYL) DEXTRO 7 PHENYLALANYL 8 ARGINYL 9 TRYPTOPHANYL 10 LYSYL]AMIDE; CYCLO[6 SUCCINYL DEXTRO 7 (2 NAPHTHYLALANYL) 8 ARGINYL 9 TRYPTOPHANYL 10 LYSYL]AMIDE; GAMMA INTERMEDIN; HORMONE; HORMONE RECEPTOR AFFECTING AGENT; HYDRO DEXTRO 4 PHENYLALANYLCYCLO(5 ASPARTYL 6 HISTIDYL DEXTRO 7 PHENYLALANYL 8 ARGINYL 9 TRYPTOPHANYL 10 LYSYL)AMIDE; INTERMEDIN; LIGAND; MBP 10; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN 2 RECEPTOR; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 3 RECEPTOR AGONIST; MELANOCORTIN 3 RECEPTOR ANTAGONIST; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 4 RECEPTOR ANTAGONIST; MELANOCORTIN 5 RECEPTOR; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; NEUROTRANSMITTER; PEPTIDE DERIVATIVE; PG 901; PG 951; PIPERAZINE DERIVATIVE; PROOPIOMELANOCORTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENAL DISEASE; ADRENAL FUNCTION; ANOREXIA; BRAIN; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENERGY BALANCE; FEEDING BEHAVIOR; GENE INTERACTION; IMMUNE RESPONSE; INFLAMMATION; MOTIVATION; NEUROPATHIC PAIN; NONHUMAN; OBESITY; PAIN; PIGMENT DISORDER; PIGMENTATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR BINDING; REVIEW; SEXUAL FUNCTION; SPINAL CORD; STRESS; SYMPATHETIC TONE;

EID: 34447263592     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780906654     Document Type: Review

References (111)

1. Krieger, D. T.; Ganong, W. F.; eds. ACTH and related peptides, structure, regulation and action. Ann. NY Acad. Sci., 1977, 297, 1-664.
2. Vaudry, H.; Eberle, A. N.; eds. The Melanotropic Peptides. Ann. N.Y. Acad. Sci., 1993, 680, 1-684.
3. Hadley, M. E.; ed. The Melanotropic Peptides. Volumes I, II & III. CRC Press, Inc.; Boca Raton, FL 1988.
4. Eberle A. N. ed. The Melanotropins; Chemistry, Physiology and Mechanisms of Action. Karger, Basel, Switzerland, 1988.
5. Cone, R. D.; ed. The Melanocortin System. Ann. N.Y. Acad. Sci., 2003, 994, 1-387.
6. Cone, R. D.; ed. The Melanocortin Receptors. Humana Press, Totowa, NJ 2000.
7. Kesterson, R. A. The melanocortin 3 receptor In The Melanocortin Receptors, Cone, R. D.; ed. Humana Press, Totowa, NJ. Chapter 13, 385-403 2000.
8. Bell, G. I.; Xiang, K. S.; Newman, M. V.; Wu, S. H.; Wright, L. G.; Fajans, S. S.; Spielman, R. S.; Cox, N. J. Gene for non-insulin-dependent diabetes-mellitus (maturity onset diabetes of the young subtype) is linked to DNA polymorphism on human chromosome-20q. Proc. Natl. Acad. Sci. USA, 1991, 88, 1484-88.
9. Yamada, Y.; Xiang, K. S.; Bell, G. I.; Seino, S.; Nishi, M. Dinucleotide repeat polymorphism in a gene on chromosome-20 encoding a 6-protein coupled receptor (D20S32E). Nucleic Acids Res., 1991, 19, 2519.
10. Marks, D. L.; Hruby, V.; Brookhart, G.; Cone, R. D. The regulation of food intake by selective stimulation of the type 3 melanocortin receptor (MC3R). Peptides, 2006, 27, 259-64.
11. Cowley, M. A.; Smart, J. L.; Rubinstein, M.; Cerdan, M. G.; Diano, S.; Horvath, T. L.; Cone, R. D.; Low, M. J. Leptin activates anorexigenic POMC neurons through a neural network in the arcuste nucleus. Nature, 2001, 411, 480-84.
12. Chen, A. S.; Marsh, D. J.; Trumbauer, M. E.; Frazier, E. G.; Guan, X. M.; Yu, H.; Rosenblum, C. I.; Vongs, A.; Feng, Y.; Cao, L. H.; Metzger, J. M.; Strack, A. M.; Camacho, R. E.; Mellin, T. N.; Nunes, C. N.; Min, W.; Fisher, J.; Gopal-Truter, S.; MacIntyre, D. E.; Chen, H. Y.; Van derPloeg, L. H. T. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet., 2000, 26, 97-102.
13. Butler, A. A.; Kesterson, R. A.; Khong, K.; Cullen, M. J.; Pelleymounter, M. A.; Dekoning, J.; Boetscher, M.; Cone, R.D. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology, 2000, 141, 3518-21.
14. Sutton, G. M.; Trevaskis, J. L.; Hulver, M. W.; McMillan, R. P.; Markward, N. J.; Babin, M. J.; Meyer, E. A.; Butler, A. A. Diet-genotype interactions in the development of the obese, insulin-resistant phenotype of C57BL/6J mice lacking melanocortin-3 or -4 receptors. Endocrinology, 2006, 147, 2183-96.
15. Gantz, I.; Miwa, H.; Konda, Y.; Shimoto, Y.; Tashiro T.; Watson S. J.; DelValle, J.; Yamada, T. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J. Biol. Chem., 1993, 268, 15174-79.
16. Getting, S. J.; Gibbs, L.; Clark, A. J. L.; Flower R. J.; Perretti, M. POMC gene derived peptides activate melanocortine type 3 receptor on murine macrophages, suppress cytokine release and inhibit neutrophil migration in acute experimental inflammation. J. Immunol., 1999, 162, 7446-53.
17. etting, S. J.; Allcock, G. H.; Flower R.; Parretti, M. Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties. J. Leukoc. Biol., 2001, 69, 98-104.
18. Getting, S. J.; Christian, H. C.; Lam, C. W.; Gavins, F. N.; Flower R. J.; Schioth, H. B.; Perretti, M. Redundancy of a functional melanocortin 1 receptor in the anti-inflammatory actions of melanocortin peptides, studies in the recessive yellow (e/e) mouse suggest an important role for melanocortin 3 receptor. J. Immunol., 2003, 170(6), 3323-30.
19. Getting, S. J.; Christian, H. C.; Flower R. J.; Perretti, M. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum., 2002, 46, 2765-75.
20. Getting, S. J.; Di Filippo, C.; Christian, H. C.; Lam, C. W.; Rossi F.; D'Amico, M.; Perretti, M. MC-3 receptor and the inflammatory mechanisms activated in acute myocardial infarct. J. Leukocyte Biol., 2004, 76, 845-53.
21. Guarini, S.; Schioth, H. B.; Mioni, C.; Cainazzo, M.; Ferrazza G.; Giuliani D.; Wikberg J. E. S.; Bertolini A.; Bazzani C. MC(3) receptors are involved in the protective effect of melanocortins in myocardial ischemia/reperfusion-induced arrhythmias. Naunyn Schmiedebergs Arch. Pharmacol., 2002, 366, 177-82.
22. Schwartz, M.; Woods, S.; Porte, D. J.; Seeley, R.; Baskin, D. Central nervous system control of food intake. Nature, 2000, 404, 661-71.
23. Ahima, R.; Flier, J. Leptin. Annu. Rev. Physiol., 2000, 62, 413-37.
24. Fan, W.; Boston, B.; Kesterson, R.; Hruby, V.; Cone, R. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature, 1997, 385, 165-68.
25. Seeley, R.; Yagaloff, K.; Fisher, S.; Burn, P.; Thiele, T.; van Dijk, G.; Baskin, D.; Schwartz, M. Melanocortin receptors in leptin effects. Nature, 1997, 390, 349.
26. Chuang T. T.; Iacovelli, L.; Sallese, M.; De Blasi, A. G. Protein-coupled receptors, heterologous regulation of homologous desensitization and its implications. Trends Pharmacol. Sci., 1996 17, 416-21.
27. Bunemann, M.; Hosey, M. G-protein coupled receptor kinases as modulators of G-protein signaling. J. Physiol., 1999, 517, 5-23.
28. Lohse, M.; Benovic, J.; Codina, J.; Caron, M.; Lefkowitz, R. ß-Arrestin, a protein that regulates ß-adrenergic receptor function. Science, 1990, 248, 1547-50.
29. Cai, M.; Stankova, M.; Pond, S. J. K.; Mayorov, A.V.; Perry, J.W.; Yamamura, H.I.; Trivedi, D.; Hruby, V.J. Real time differentiation of G-protein coupled receptor (GPCR) agonist and antagonist by two photon fluorescence laser microscopy. J. Am. Chem. Soc., 2004, 26, 7160-61.
30. Zhang, J.; Barak, L. S.; Winkler, K. E.; Caron, M. G.; Ferguson, S. S. G. A central role for ß-arrestins and clathrin-coated vesicle-mediated endocytosis in ß2-adrenergic receptor resensitization. Differential regulation of receptor resensitization in two distinct cell types. J. Biol. Chem., 1997, 272, 27005-14.
31. Oakley, R. H.; Laporte, S. A.; Holt, J. A.; Barak, L. S.; Caron, M. G. Association of ß-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J. Biol. Chem., 1999, 274, 32248-57.
32. Tsao, P.; Cao, T.; von Zastrow, M. Role of endocytosis in mediating downregulation of G-protein-coupled receptors. Trends Pharmacol. Sci., 2001, 22, 91-6.
33. Tsao, P. I.; von Zastrow, M. Diversity and specificity in the regulated endocytic membrane trafficking of G-protein-coupled receptors. Pharmacol. Ther., 2001, 89, 139-47.
34. Nestler, E. Molecular basis of long-term plasticity underlying addiction. Nat. Rev. Neurosci., 2001, 2, 119-28.
35. Harrison, L.; Kastin, A.; Zadina, J. Opiate tolerance and dependence, receptors, G-proteins, and antiopiates. Peptides, 1998, 19, 1603-30.
36. Yang, Y.; Chen, M.; Loux, T. J.; Georgeson, K. E.; Harmon, C. M. Molecular mechanism of the intracellular segments of the melanocortin-4 receptor for NDP-MSH signaling. Biochemistry, 2005, 44, 6971-79.
37. Hruby, V. J. Conformational restrictions of biologically active peptides via amino acid side chain groups. Life Sci., 1982, 31, 189-92.
38. Popov, E. M.; Akhmedov, N. A.; Makhmudova, T. A. Approach to studying the structure-activity relationship of native peptides. I. Structural organization of the opioid peptide Tyr-Glu-Gly-Phe-Met-Arg-Gly-Leu and its artificial analogs. Bioorganicheskaia khimiia, 1992, 18, 1454-63.
39. Kessler, H. Conformational and Biological Activity of Cyclic Peptides. Angew. Chem. Int. Ed. End., 1982, 21, 512-23
40. Sawyer, T. K. Peptidomimetic and Nonpeptide Drug Discovery, Impact of Structure-Based Drug Design. In Structure Based Drug Design, Disease, Targets, Techniques and Developments. P. Veerapandian, Ed.; Macel Dekker, N.Y. Chapter 23 1997; pp. 559-634.
41. Hruby, V. J. Designing peptide receptor agonists and antagonists. Nat. Drug Des, 2002, 1, 847-58.
42. Hirschmann R. Medicinal chemistry in the golden age biology, lessons from steroid and peptide research. Angew. Chem. Int. Ed. Eng., 1991, 30, 1278-1301.
43. 8 on human MC3 receptor selectivity. J. Med. Chem., 2000, 43, 4998-5002.
44. Bystrov, V.F.; Okhanov, V.V.; Miroshnikov, A.I.; Ovchinnikov, Y.A. Solution spatial structure of apamin as derived from NMR study. FEBS Letter, 1980, 119, 113-7.
45. Hruby, V.J. The conformation of peptides in solution as determined by NMR spectroscopy and other physical methods. In Chemistry and Biochemistry of Amino Acids, Peptides and Proteins. Weinstein, B.; ed. Marcel Dekker, New York, NY 1974, p 1-188.
46. Marraud, M.; Aubry, A. Crystal structures of peptides and modified peptides. Biopolymers, 1996, 40, 45-8.
47. Woody, R.W. Contributions of tryptophan side chains to the far-ultraviolet circular dichroism of proteins. Circ. Dichroism., 1994, 47, 3.
48. Scheraga, H.A. Contribution of physical chemistry to an understanding of protein structure and function. Protein Science., 1992, 1, 691-3.
49. Cone, R D. Melanocortin system. Encyclopedia Biol. Chem., 2004, 2, 617-20.
50. Hruby, V.J.; Wilkes, B.C.; Hadley, M.E.; Al-Obeidi, F.; Sawyer, T.K.; Staples, D.J.; de Vaux, A.E.; Dym, O.; de Lauro Castrucci, A.-M.; Hintz, M.F.; Riehm, J.R.; Rao, R.R. α-Melanotropin, the minimum active sequence in the frog skin bioassay. J. Med. Chem., 1987, 30, 2126-30.
51. de Lauro Castrucci, A.-M.; Hadley, M.E.; Sawyer, T.K.; Wilkes, B.C.; Al-Obeidi, F.; Staples, D.J.; de Vaux, A.E.; Dym, O.; Hintz, M.F.; Riehm, J.P.; Rao, R.R.; Hruby, V.J. α-Melanotropin, the minimal active sequence in the lizard skin bioassay. Gen. Comp. Endocrinol., 1989, 73, 157-63.
52. Cai, M.; Mayorov, A.V.; Cabello, C.; Stankova, M.; Trivedi D.; Hruby, V.J. Novel 3D pharmacophore of α-MSH/γ-MSH hybrids leads to selective human MC1R and MC3R analogues. J. Med. Chem., 2005, 48, 1839-48.
53. 2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J. Med. Chem., 1995, 38,3454-61.
54. Balse-Srinivasan P.; Grieco, P.; Cai, M.; Trivedi, D.; Hruby, V.J. Structure-activity relationships of gamma-MSH analogues at the human melanocortin MC3, MC4, and MC5 receptors. Discovery of highly selective hMC3R, hMC4R, and hMC5R analogues. J. Med. Chem., 2003, 46, 4965-73.
55. Sawyer, T.K.; Hruby, V.J.; Darman, P.S.; Hadley, M.E. [4-half-cystine, 10-half-cystine]-α-Melanocyte stimulating hormone, a cyclic α-melanotropin exhibiting superagonist biological activity. Proc. Nat. Acad. Sci USA, 1982, 79, 1751-55.
56. 10]melanotropin analogues. J. Med. Chem., 1993, 28, 125-29.
57. Al-Obeidi, F.; Hadley, M.E.; Pettitt, B.M.; Hruby, V.J. Design of a new class of superpotent cyclic α-melanotropins based on quenched dynamic simulations. J. Am. Chem. Soc., 1989, 111, 3413-16.
58. Al-Obeidi, F.; de Lauro Castrucci, A.-M.; Hadley, M.E.; Hruby, V.J. Potent and prolonged acting cyclic lactam analogues of α-melanotropin, design based on molecular dynamics. J. Med. Chem., 1989, 32, 2555-61.
59. Hruby, V.J.; Cai, M.; Grieco, P.; Han, G.; Kavarana, M.; Trivedi, D. Exploring the stereostructural requirements of peptide ligands for the melanocortin receptors. Ann. N.Y. Acad. Sci., 2003, 994, 12-20.
60. Kavarana, M.J.; Trivedi, D.; Cai, M.; Ying, J.; Hammer, M.; Cabello, C.; Grieco, P.; Han, G.; Hruby, V.J. Novel cyclic templates of a-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J. Med. Chem., 2002, 45, 2644-50.
61. Grieco P.; Lavecchia A.; Cai M.; Trivedi D.; Weinberg D.; MacNeil T.; Van der Ploeg, L. H. T.; Hruby, V. J. Structure-Activity Studies of the Melanocortin Peptides, Discovery of Potent and Selective Affinity Antagonists for the hMC3 and hMC4 Receptors. J. Med. Chem., 2002, 45, 5287-5294.
62. Grieco, P.; Cai, M.; Mayorov, A. V.; Trivedi D.; Hruby, V. J. Structure-activity studies of new melanocortin peptides containing an aromatic amino acid at the N-terminal position. Peptides, 2006, 27(2), 472-481.
63. Balse-Srinivasan, P.; Grieco, P.; Cai, M.; Trivedi, D.; Hruby, V. J. Structure-Activity Relationships of Novel Cyclic α-MSH/β-MSH Hybrid Analogues That Lead to Potent and Selective Ligands for the Human MC3R and Human MC5R. J. Med. Chem., 2003, 46, 3728-3733.
64. Cai, M.; Cai, C.; Mayorov, A.V.; Xiong, C.; Cabello, C.M.; Soloshonok, V.A.; Swift, J.R.; Trivedi, D.; Hruby V.J. Biological and conformational study of beta-substituted prolines in MT-II template, steric effects leading to human MC5 receptor selectivity. J. Pep. Res., 2004, 63, 116-31.
65. Wang, W.; Cai, M.; Xiong, C.; Zhang, J.; Trivedi, D.; Hruby, V.J. Design and synthesis of novel χ2-constrained phenylalanine, naphthylalanine, and tryptophan analogs and their use in biologically active melanotropin peptides. Tetrahedron, 2002, 58, 7365-74.
66. Jackson, P.J.; McNulty, J.C.; Yang, Y-K.; Thompson, D.A.; Chai, B.; Gantz, I.; Barsh, G.S.; Millhauser, G.L. Design, pharmacology, and NMR structure of a minimized cystine knot with agouti-related protein activity. Biochemistry, 2002, 41, 7565-72.
67. Ying, J; Kövér, K. E.; Gu, X.; Han, G.; Trivedi, D. B.; Kavarana, M. J.; Hruby, V. J. Solution Structures of Cyclic Melanocortin Agonists and Antagonists by NMR. Biopolymers (Peptide Science), 2003, 71, 696-716.
68. Grieco, P.; Han, G.; Weinberg, D.; MacNeil, T.; Van der Ploeg, L. H. T.; Hruby, V. J. Design and Synthesis of Highly Potent and Selective Melanotropin Analogues of SHU9119 Modified at Position 6. Biochem. Biophys. Res. Comm., 2002, 292, 1075-1080.
69. Mayorov, A. V.; Cai, M.; Chandler, K. B.; Petrov, R. R.; Van Scoy, A. R.; Yu, Z.; Tanaka, D. K.; Trivedi, D.; Hruby V. J. Development of cyclic γ-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J. Med. Chem., 2006, 49, 1946-52.
70. Mayorov, A. V.; Cai, M.; Han, S.-Y.; Tan, B.; Van Scoy, A. R.; Dedek, M.; Palmer, E. S.; Trivedi, D.; Hruby, V. J. Novel cyclic lactam α-MSH analogs as potent and selective hMC3R agonists and antagonists, and hMC1R antagonists. Abstracts of Papers, 232nd ACS National Meeting, San Francisco, CA, United States, Sept. 10-14, 2006, MEDI-414.
71. Ballet, S.; Mayorov, A. V.; Cai, M.; Tymecka, D.; Chandler, K. B.; Palmer, E. S.; Van Rompaey, K.; Misicka, A.; Tourwé, D.; Hruby, V. J. Novel selective human melanocortin-3 receptor ligands, use of the 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (Aba) scaffold. Bioorg. Med. Chem. Lett., 2007, 71, 2492-2498.
72. Bednarek, M. A.; MacNeil, T.; Kalyani, R. N.; Tang, R.; Van der Ploeg, L. H. T.; Weinberg, D. H. Selective, High Affinity Peptide Antagonists of α-Melanotropin Action at Human Melanocortin Receptor 4, Their Synthesis and Biological Evaluation in vitro. J. Med. Chem., 2001, 44, 3665-3672.
73. Sebhat, I.K.; Martin, W.J.; Ye, Z.; Barakat, K.; Mosley, R.T.; Johnston, D.B.R.; Bakshi, R.; Palucki, B.; Weinberg, D.H.; MacNeil, T.; Kalyani, R.N.; Tang, R.; Stearns, R.A.; Miller, R.R.; Tamvakopoulos, C.; Strack, A.M.; McGowan, E.; Cashen D.E.; Drisko, J.E.; Hom, G.J.; Howard, A.D.; MacIntyre, D.E.; Van Der Ploeg, L.H.T.; Patchett, A.A.; Nargund, R.P. Design and Pharmacology of N-[(3R)-1,2,3,4-Tetrahydroisoquinolimium-3- ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H - 1,2,4-triazol-1- ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a Potent, Selective, Melanocortin Subtype-4 Receptor Agonist. J. Med. Chem., 2002, 45, 4589-4593.
74. Dyck, B.; Parker, J.; Phillips, T.; Carter, L.; Murphy, B.; Summers, R.; Hermann, J.; Baker, T.; Cismowski, M.; Saunders, J.; Goodfellow, V. Aryl Piperazine Melanocortin MC4 Receptor Agonists. Bioorg. Med. Chem. Lett., 2003, 13, 3793-3796.
75. Mutulis, F.; Yahorava, S.; Mutule, I.; Yahorau, A.; Liepinsh, E.; Kopantshuk, S.; Veiksina, S.; Tars, K.; Belyakov, S.; Mishnev, A.; Rinken, A.; Wikberg, J.E.S. New Substituted Piperazines as Ligands for Melanocortin Receptors. Correlation to the X-ray Structure of "THIQ". J. Med. Chem., 2004, 47, 4613-4626.
76. Richardson, T.I.; Ornstein, P.L.; Briner, K.; Fisher, M.J.; Backer, R.T.; Biggers, C. K.; Clay, M.P.; Emmerson, P.J.; Hertel, L.W.; Hsiung, H.M.; Husain, S.; Kahl, S.D.; Lee, J.A.; Lindstrom, T.D.; Martinelli, M.J.; Mayer, J.P.; Mullaney, J.T.; O'Brien, T.P.; Pawlak, J.M.; Revell, K.D.; Shah, J.; Zgombick, J.M.; Herr, R.J.; Melekhov, A.; Sampson, P.B.; King, C.R. Synthesis and Structure-Activity Relationships of Novel Arylpiperazines as Potent and Selective Agonists of the Melanocortin Subtype-4 Receptor. J. Med. Chem., 2004, 47, 744-755.
77. Herpin, T.F.; Yu, G.; Carlson, K.E.; Morton, G.C.; Wu, X.; Kang, L.; Tuerdi, H.; Khanna, A.; Tokarski, J.S.; Lawrence, R.M.; Macor, J.E. Discovery of Tyrosine-Based Potent and Selective Melanocortin-1 Receptor Small-Molecule Agonists with Anti-inflammatory Properties. J. Med. Chem., 2003, 46, 1123-1126.
78. Palucki, B.L.; Park, M.K.; Nargund, R.P.; Ye, Z.; Sebhat, I.K.; Pollard, P.G.; Kalyani, R.N.; Tang, R.; MacNeil, T.; Weinberg, D.H.; Vongs, A.; Rosenblum, C.I.; Doss, G.A.; Miller, R.R.; Stearns, R.A.; Peng, Q.; Tamvakopoulos, C.; McGowan, E.; Martin, W.J.; Metzger, J.M.; Shepherd, C.A.; Strack, A.M.; MacIntyre, D.E.; Van der Ploeg, L.H.T.; Patchett, A.A. Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4- (1,1-dimethylethyl)-amino] carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4- methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist. Bioorg. Med. Chem. Lett., 2005, 15, 171-175.
79. Pogozheva, I.D.; Chai, B.; Lomize, A.L.; Fong, T.M.; Weinberg, D.H.; Nargund, R.P.; Mulholland, M.W.; Gantz, I.; Mosberg, H.I. Interactions of Human Melanocortin 4 Receptor with Nonpeptide and Peptide Agonists. Biochemistry, 2005, 44, 11329-11341.
80. 2. Bioorg. Med. Chem. Lett., 2003, 13, 2337-2340.
81. Cain, J.P.; Mayorov, A.V.; Cai, M.; Wang, H.; Tan, B.; Chandler, K.; Lee, Y.S.; Petrov, R.R.; Trivedi, D.; Hruby, V.J. Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors. Bioorg. Med. Chem. Lett., 2006, 16, 5462-67.
82. Ujjainwalla, F.; Warner, D.; Walsh, T.F.; Wyvratt, M.J.; Zhou, C.; Yang, L.; Kalyani, R.N.; MacNeil, T.; Van der Ploeg, L.H.T.; Rosenblum, C.I.; Tang, R.; Vongs, A.; Weinberg, D.H.; Goulet, M.T. Design and Syntheses of Melanocortin Subtype-4 Receptor Agonists, Evolution of the Pyridazinone Archetype. Bioorg. Med. Chem. Lett., 2003, 13, 4431-4435.
83. Ghose, A.K.; Herbertz, T.; Salvino J.M and Mallamo J. P1 Knowledge-based chemoinformatic approaches to drug discovery. Drug Discov. Today, 2006, 11, 1107-1114.
84. Sheridan R.P. and Kearsley S. K. Why do we need so many chemical similarity search methods. Drug Discov. Today, 2002, 7, 903-911
85. Balakin K.V.; Lang S. A.; Skorenko, A.V.; Tkachenko, S. E. Ivashchenko, A A.; and Savchuk N. P.; Structure-Based versus property-based approaches in the design of G-Protein-coupled receptor-targeted libraries. J. Chem. Inf. Compul. Aci., 2003, 43, 1553-1562.
86. Vos, T. J.; Caracoti, A.; Che, J. L.; Dai, M.; Farrer, C. A.; Forsyth, N. E.; Drabic, S. V.; Horlick, R. A.; Lamppu, D.; Yowe, D. L.; Balani, S.; Li P.; Zeng, H.; Joseph, I. B.; Rodriguez, L. E.; Maguire, M. P.; Patane, M. A.; and Claiborne, C. F. Identification of 2-[2-[2-(5-bromo-2- metboxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML0053764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. J. Med. Chem., 2004, 47, 1602-1604.
87. Pontillo, J.; Tran, J. A.; Fleck, B. A.; Marinkovic, D.; Arellano, M.; Tucci, F. C.; Lanier, M.; Nelson, J.; Parker, J.; Saunders, I.; Murphy, B.; Foster, A. C.; and Chen, C. Piperazinebenzylamines as potent and selective antagonists of the human melanooortin-4 receptor, Bioorg. Med. Chem. Lett., 2004, 14, 5605-5609.
88. Tucci, F. C.; White, N. S.; Markison, S.; Joppa, M.; Tran, J. A.; Fleck, B. A.; Madan, A.; Dyck, B. P.; Parker, J.; Pontillo, J.; Arellano, L. M.; Marinkovic, D.; Jiang, W.; Chen, C. W.; Gogas, K. R.; Goodfellow, V. S.; Saunders, J.; Foster, A. C.; Chen, C. Potent and orally active non-peptide antagonists of the human melanocortin-4 receptor based on a series of trans-2-disubstituted cyclohexylpiperazines, Bioorg. Med. Chem. Lett., 2005, 15, 4389-4395.
89. Prusis, P.; Frändberg, P,-A.; Muceniece, R.; Kalvinsh, I.; Wikberg, J.E.S. A three dimensional model for the interaction of MSH with die melanocortin-1 receptor. Biochem. Biophy. Res. Commun., 1995, 210, 205-10.
90. Chen, M.; Aprahamian, C.J.; Celik, A.; Georgeson, K.E.; Garvey, W.T.; Harmon, C.M.; Yang, Y. Molecular characterization of human melanocortin-3 receptor ligand-receptor interaction. Biochemistry, 2006, 45, 1128-37.
91. Yang, Y.K.; Fong, T.M.; Dickinson, C.J.; Mao, C.; Li, J.Y.; Tota, M.R.; Mosley, R.; Van Der Ploeg, L.H.T.; Gantz, I. Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry, 2000, 39, 14900-11.
92. Yang, Y.; Dickinson, C.; Haskell-Luevano, C.; Gantz, I. Molecular basis for the interaction of [Nle4, D-Phe7]melanocyte stimulating hormone with the human melanocortin-1 receptor. J. Biol. Chem., 1997, 272, 23000-10.
93. Tao, Y.X.; Segaloff, D.L. Functinal characterization of melanocortin-3 receptor variants identify a loss-of-function mutation involving an amino acid critical for G protein-coupled receptor activation. J. Clin. Endocrinol. Metab., 2004, 89, 3936-42.
94. Ellacott, K. L. J.; Cone, R. D. The Central Melanocortin System and the Integration of Short- and Long-term Regulators of Energy Homeostasis. Rec. Prog. Horm. Res., 2004, 59, 395-408.
95. Krude, H.; Biebermann, H.; Luck, W.; Horn, R.; Brabant, G.; Gruters, A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat. Genet., 1998, 19, 155-7.
96. Clement, K.; Vaisse, C.; Lahlou, N.; Cabrol, S.; Pelloux, V.; Cassuto, D.; Gourmelen, M.; Dina, C.; Chambaz, J.; Lacorte, J.M.; Basdevant, A.; Bougneres, P.; Lebouc, Y.; Froguel, P.; Guy-Grand, B. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature, 1998, 392, 398-401.
97. Cowley, M.A.; Pronchuk, N.; Fan, W.; Dinulescu, D.M.; Colmers, W.F.; Cone, R.D. Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventicular nucleus, evidence of a cellular basis for the Adipostat. Neuron, 1999, 24, 155-63.
98. Ollmann, M.M.; Wilson, B.D.; Yang, Y.; Kerns, J.A.; Chen, Y.; Gantz, I.; Barsh, G.S. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997, 278, 137.
99. Fong, T.M.; Mao, C.; MacNeil, C.; Kalyani, R.; Smith, T.; Weinberg, D.; Tota, M.R.; Van der Ploeg, L.H. ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors. Biochem. Biophys. Res. Commun., 1997, 237, 629-31.
100. Gantz, I.; Konda, Y.; Shimoto, Y.; Miwa, H.; Munzert, G.; Watson, S.J.; Del Valle, V.; Yamada, T. Molecular cloning of a novel melanocortin receptor. J. Biol. Chem., 1993, 268, 8246-50.
101. Roselli-Rehfuss, L.; Mountjoy, K.G.; Robbins, L.S.; Mortrud, M.T.; Low, M.J.; Tatro, J.B.; Entwistle, M.L.; Simerly, R.B.; Cone, R.D. Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbric system. Proc. Natl. Acad. Sci., 1993, 90, 8856-60.
102. Mountjoy, K.G.; Mortrud, M.T.; Low, M.J.; Simerly, R.B.; Cone, R.D. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol. Endocrinol., 1994, 8, 1298-1308.
103. Fan, W.; Boston, B.A.; Kesterson, R.A.; Hruby, V.J.; Cone, R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature, 1997, 385, 165-8.
104. Raffin-Samson, M.L.; Bertherat, J. Mc3 and Mc4 receptors, complementary role in weight control. Eur. J. Endocrinol., 2001, 144, 207-8.
105. Getting, S.J.; Gibbs, L.; Clark, A.J.L.; Flower, R.J.; Perretti, M. POMC gene derived peptides activate melanocortin type 3 receptor on murine macrophages, suppress cytokine release and inhibit neutrophil migration in acute experimental inflammation. J. Immunol., 1999, 162, 7446-53.
106. Abbott, C.R.; Rossi, M.; Kim M.; Al Ahmed, S.H.; Taylor, G.M.; Ghatei, M.A.; Smith, D.M.; Bloom, S.R. Investigation of the melanocyte stimulating hormones on food intake. Lack of evidence to support a role for the melanocortin-3-receptor. Brain Res., 2000, 869, 203-10.
107. Versteeg, D.H.G.; Bergen, P.V.; Adan, R.A.H.; DeWildt, D.J. Melanocortins and cardiovascular regulation. Eur. J. Pharmacol., 1998, 360, 1-14.
108. Li, S-J.; Varga, K.; Archer, P.; Hruby, V.J.; Sharma, S.D.; Kesterson, R.A.; Cone, R.D.; Kunos, G. Melanocortin Antagonists Define Two Distinct Pathways of Cardiovascular Control by α- and γ-Melanocyte-Stimulating Hormones. J. Neurosci., 1996, 16, 5182-88.
109. Kim M.S.; Russell, S.H.; Morgan, D.G.A.; Abbott, C.R.; Al Ahmed, S.H.; Hay, D.L.; Ghatei, MA.; Smith, D.M.; Bloom, S.R. Effects of melanocortin receptor ligands on thyrotropin-releasing hormone release, evidence for the differential roles of melanocortin 3 and 4 receptors. J. Neuroendocrinol., 2002, 14, 276-82.
110. Marks, D. L.; Hruby, V. J.; Brookhart, G.; Cone, R. D. The regulation of food intake by selective stimulation of the type 3 melanocortin receptor (MC3R). Peptides, 2006, 27, 259-264.
111. Marks, D.L.; Cone, R.D. Central melanocortins and the regulation of weight during acute and chronic disease. Recent Prog. Horm. Res., 2001, 56, 359-75.